Universal administration of high-flow oxygen therapy for all acute coronary syndrome patients may not be beneficial, except for hypoxic ST-segment elevation MI (STEMI) patients, according to study results presented at ESC 2019 in Paris.
High-flow oxygen given irrespective of saturation levels until ischemia resolves held no impact on 30-day mortality compared with only giving oxygen when saturation drops below 90% and stopping once it normalizes.
STEMI patients, though, had a significant 19% lower relative risk of 30-day mortality with the high oxygen protocol (8.8% vs 10.6%, P=0.016 for interaction) not seen in other ACS patients.
